-
Ocular Immunology and Inflammation Oct 2020: To identify prognosis factors and functional outcomes of persistent placoid maculopathy (PPM). : We collected personal PPM cases and combined them with the data from...
: To identify prognosis factors and functional outcomes of persistent placoid maculopathy (PPM). : We collected personal PPM cases and combined them with the data from the literature. : 68 eyes of 37 patients with PPM were analyzed, including six new cases. Twenty-six patients were men (70%) with a mean age of 51.8 years old. The mean initial visual acuity (VA) was 0.52 LogMar ± 0.55 for a mean final VA of 0.49 LogMar ± 0.51. Risk factors for poor VA included: initial VA less than 0.2 LogMar ( < .0001), cardiovascular risk factor ( = .008), autoimmune-related and/or systemic pro-inflammatory conditions ( = .003), choroidal neovascularization ( = .001), macular atrophy ( = .03) and absence of systemic corticosteroid treatment ( = .03). : PPM is a choroidal inflammation. Identifying prognosis factors may help to guide treatment and follow-up. We showed that anti-inflammatory drugs, and anti-VEGF injections in cases of choroidal neovascularization, may lead to better outcomes.
Topics: Adult; Aged; Angiogenesis Inhibitors; Choroidal Neovascularization; Choroiditis; Coloring Agents; Female; Fluorescein Angiography; Glucocorticoids; Humans; Immunosuppressive Agents; Indocyanine Green; Male; Middle Aged; Multimodal Imaging; Prognosis; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity
PubMed: 31419178
DOI: 10.1080/09273948.2019.1645187 -
Human Vaccines & Immunotherapeutics Dec 2024Considering the widespread use of COVID-19 vaccines as a preventive measure against the spread of the virus, it's necessary to direct attention to the adverse effects...
Considering the widespread use of COVID-19 vaccines as a preventive measure against the spread of the virus, it's necessary to direct attention to the adverse effects associated with vaccines in a limited group of populations. Multiple evanescent white dot syndrome (MEWDS) following COVID-19 vaccination is a rare adverse reaction associated with COVID-19 vaccines. In this systematic review, we collected 19 articles with 27 patients up to November 1, 2023, summarizing the basic information, clinical manifestations, examinations, treatments, and recoveries of the 27 patients. The 27 enrolled patients (6 males, 21 females) had a median age of 34.1 years (15-71 years old) and were mainly from 5 regions: Asia (8), the Mediterranean region (8), North America (7), Oceania (3) and Brazil (1). Symptoms occurred post-first dose in 9 patients, post-second dose in 14 (1 with symptoms after both), post-third dose in 1, and both post-second and booster doses in 1, while details on 2 cases were not disclosed. Treatments included tapered oral steroids (6), topical steroids (3), tapered prednisone with antiviral drugs and vitamins (1), and valacyclovir and acetazolamide (1), while 16 received no treatment. All patients experienced symptom improvement, and nearly all patients ultimately recovered. Moreover, we summarized possible hypotheses concerning the mechanism of COVID-19 vaccine-associated MEWDS. The findings provide insights into the clinical aspects of COVID-19 vaccine-associated MEWDS. More attention should be given to patients with vaccine-associated MEWDS, and necessary treatment should be provided to patients experiencing a substantial decline in visual acuity to improve their quality of life.
Topics: Humans; Adult; COVID-19 Vaccines; Young Adult; Male; Female; Middle Aged; Adolescent; COVID-19; Aged; White Dot Syndromes; SARS-CoV-2
PubMed: 38752704
DOI: 10.1080/21645515.2024.2350812